(Reuters) – AstraZeneca said on Monday its cancer drug Enhertu helped patients with a type of advanced breast cancer live longer without their condition worsening versus chemotherapy, potentially widening the drug’s use.
The drug, developed with Japan’s Daiichi Sankyo, showed an improvement in progression-free survival and overall survival in certain cancer patients regardless of their hormone receptor status.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Shounak Dasgupta)
